Overview: Cholera (Vibrio cholerae) Antigen Rapid TestIntroduction: The Cholera (Vibrio cholerae) Antigen Rapid Test is a diagnostic tool designed to detect Vibrio cholerae antigens in stool or rectal swab samples, facilitating the screening of cholera. Caused by the bacterium Vibrio cholerae, this acute diarrheal disease is a major public health threat in endemic regions, presenting with severe watery diarrhea, dehydration, and complications like hypovolemic shock or death if untreated, particularly in areas with poor sanitation. Per the 2023 World Health Organization guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis during outbreaks or humanitarian crises. This rapid diagnostic falls under bacteriology and targets individuals with acute watery diarrhea, addressing the challenge of identifying cholera among other diarrheal diseases to guide rehydration and antibiotic therapy with doxycycline or azithromycin. With morbidity rates elevated due to rapid dehydration, the test supports public health efforts by enabling early case detection, facilitating water sanitation measures, and preventing epidemic spread. Its field usability enhances its value in resource-limited settings.Other Names: Cholera Rapid Test.FDA Status: FDA approved, CLIA certified for bacteriology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Alere, this test advanced cholera detection, providing a rapid alternative to culture-based methods.Purpose: The test screens for Vibrio cholerae antigens to guide cholera diagnosis, assess disease severity, and inform treatment and prevention strategies.Test Parameters: Presence of Vibrio cholerae Antigen, detected with high specificity to indicate active infection, typically detectable during the acute phase, peaking within 1-3 days of symptom onset.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report severe diarrhea, dehydration, or recent travel to endemic areas.Specimen: Stool 5-10 gm, Rectal Swab 1-2 swabs, collected using sterile containers or swabs/transport medium, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on severe diarrhea, dehydration, vomiting, or recent exposure to contaminated water/food, as well as any prior cholera outbreaks.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including death, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or antibiotic pre-treatment can affect results. Correlation with stool culture or PCR is recommended to confirm findings.Clinical Significance: A positive result indicates cholera infection, necessitating immediate rehydration and antibiotics. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the antigen peak window.Specialist Consultation: Infectious disease specialists or public health officials should be consulted for case management, treatment planning, and coordination with outbreak response teams.Additional Supporting Tests: Stool culture, Vibrio cholerae PCR, or serology for confirmation.Test Limitations: The test may produce false negatives in late infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes microbiological confirmation.References: WHO Guidelines 2023, Journal of Infectious Diseases 2024, Tropical Medicine and International Health 2025.